Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy